Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer
Nitin Roper, Anna‐Leigh Brown, Jun S. Wei, Svetlana Pack, Christopher Trindade, Chul Kim, Olivia Restifo, Shaojian Gao, Sivasish Sindiri, Farid Rashidi Mehrabadi, Rajaâ El Meskini, Zoë Weaver Ohler, Tapan K. Maity, Abhilash Venugopalan, Constance M. Cultraro, Elizabeth Akoth, Emerson Padiernos, Haobin Chen, Aparna H. Kesarwala, Dee Dee Smart, Naris Nilubol, Arun Rajan, Zofia Piotrowska, Liqiang Xi, Mark Raffeld, Anna R. Panchenko, S. Cenk Şahinalp, Stephen M. Hewitt, Chuong D. Hoang, Javed Khan, Udayan Guha
Abstract
fusions. The subclonal co-occurrence of acquired genomic alterations upon osimertinib resistance will likely require targeting multiple resistance mechanisms by combination therapies.
Topics & Concepts
OsimertinibKRASCancer researchLung cancerAdenocarcinomaBiologySomatic evolution in cancerAcquired resistanceMutationGene duplicationMedicineCancerGeneGeneticsPathologyLung Cancer Treatments and MutationsLung Cancer Research StudiesCholangiocarcinoma and Gallbladder Cancer Studies